Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Taiwan Set To Approve Human Trials Of Locally Made Bird Flu Vaccine

This article was originally published in PharmAsia News

Executive Summary

Taiwanese health authorities expect the nation's emergency H5N1 vaccine to undergo its first human clinical trial by the end of this year. The vaccine was developed by the National Health Research Institute to use only in case of an emergency outbreak of the bird flu virus. The Department of Health is expected to authorize the trials by July 1. The restriction to emergencies only results from the institute's limited capacity to produce the vaccine, but DoH is seeking a partner in the private sector to enable greater production. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts